SCHEMBL25877004

SCHEMBL25877004

COc1cc(-c2nc3cc(F)ccc3s2)cc(O)c1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.70
ALDH1A1 P00352 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
MAPT P10636 3/20 0.53
KDM4E B2RXH2 3/20 0.53
HPGD P15428 3/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
RAB9A P51151 2/20 0.53
NPC1 O15118 2/20 0.53
TP53 P04637 2/20 0.53
GLA P06280 1/20 0.53
GAA P10253 1/20 0.53
PPARG P37231 1/20 0.53
NCOA2 Q15596 1/20 0.53
NCOA1 Q15788 1/20 0.53
HCRTR1 O43613 1/20 0.53
MAPK1 P28482 1/20 0.53
BLM P54132 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25876975 0.90 AHR (0.67) AHRALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL24140755 0.90 AHR (0.67) AHRALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL24140752 0.89 AHR (0.66) AHRALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL4803129 0.87 AHR (0.79) AHRALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL4803017 0.87 AHR (0.79) AHRALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL4802899 0.85 AHR (0.76) AHRALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL4797786 0.83 AHR (1.00) AHRALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL24140789 0.83 KDM4E (0.76) ALDH1A1SMN1; SMN2MAPTKDM4EHPGD
SCHEMBL30288215 0.83 AHR (1.00) AHRALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL30307425 0.83 AHR (1.00) AHRALDH1A1SMN1; SMN2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF FEN1, ERCC4, DCLRE1B AHR 4597/4885ALDH1A1 1451/4885SMN1; SMN2 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.